ICLE 2022 | Harnessing lipid-specific TCRs to target CD1c-expressing leukemia

Michela Consonni, PhD, San Raffaele Scientific Institute, Millan, Italy, discusses strategies to utilize CD1c-restricted T lymphocytes to target CD1c+ leukemia cells, which express methyl-lysophosphatidic acids (mLPAs). Out of the five CD1c self-reactive T cell clones created, DN4.99 TCR-T cells were found to target CD1c-expressing leukemia the most efficiently without killing normal cells. Dr Consonni additionally discusses efforts to enhance the avidity of the T-cell product, as well as generating novel CD1c-expressing mouse models to further assess the safety and efficacy of these engineered T-cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.